Analyst Price Targets — CMPX
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| June 1, 2026 11:32 am | Stephen Willey | Stifel Nicolaus | $6.00 | $2.38 | StreetInsider | Compass Therapeutics (CMPX) Reiterated at Buy by Stifel After ASCO Presentation |
| March 5, 2026 9:33 pm | Maury Raycroft | Jefferies | $9.00 | $5.53 | StreetInsider | Compass Therapeutics (CMPX) PT Raised to $9 at Jefferies |
| February 13, 2026 1:13 pm | — | Craig-Hallum | $15.00 | $6.52 | TheFly | Compass Therapeutics initiated with a Buy at Craig-Hallum |
| February 4, 2026 11:36 am | — | Canaccord Genuity | $13.00 | $6.42 | TheFly | Compass Therapeutics price target raised to $13 from $10 at Canaccord |
| January 6, 2026 3:11 pm | Sean McCutcheon | Raymond James | $9.00 | $4.89 | StreetInsider | Raymond James Reiterates Outperform Rating on Compass Therapeutics (CMPX) |
| December 3, 2025 10:02 am | Reni Benjamin | JMP Securities | $10.00 | $5.22 | TheFly | Compass Therapeutics initiated with an Outperform at Citizens JMP |
| October 6, 2025 10:30 am | — | Compass Point | $10.00 | $3.70 | TheFly | Compass Therapeutics initiated with an Outperform at LifeSci Capital |
| April 2, 2025 10:17 am | Andrew Berens | Leerink Partners | $6.00 | $1.69 | TheFly | Compass Therapeutics upgraded to Outperform from Market Perform at Leerink |
| September 16, 2024 6:49 am | Aydin Huseynov | Compass Point | $5.00 | $1.65 | StreetInsider | Ladenburg Thalmann Upgrades Compass Therapeutics (CMPX) to Buy |
Latest News for CMPX
BOSTON, July 17, 2026 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today announced that its abstract titled “A randomized trial of paclitaxel ± tovecimig in previously treated patients with advanced biliary tract cancer” has been accepted for an oral…
Compass Therapeutics is rated Buy, with risk/reward favoring upside after a sharp post-data selloff. CMPX's lead asset, tovecimig, showed strong PFS benefit in BTC, but OS crossover contamination clouds FDA approval prospects. The Q3 2026 FDA meeting is pivotal; approval could nearly double the stock, while rejection risks 50% dilution and multi-year delays.
Compass Therapeutics, Inc. (CMPX) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Compass Therapeutics NASDAQ: CMPX Chief Executive Officer Tom Schuetz said the company is preparing for a key U.S. Food and Drug Administration meeting on tovecimig, its DLL4/VEGF bispecific antibody, after a randomized study in advanced biliary tract cancer met its primary endpoint and a key secondary endpoint.
BOSTON, May 28, 2026 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today announced that the Company will participate in the following investor events during the month of June.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for CMPX.
U.S. House Trading
No House trades found for CMPX.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.